Abstracts tagged "autoimmune diseases"

Abstract Number: PP05 • ACR Convergence 2025
Mastering a Rare, Autoimmune Disease: My Journey Regaining Agency Through Education, Collaboration, and Community
Mustafa Shameem

Background/Purpose: After a complex diagnostic journey, my PCP working on a rheumatological theory ordered a myositis-specific autoantibody (MSA) panel. It revealed the presence of an…
Abstract Number: 2600 • ACR Convergence 2025
Deconstructing Lupus Nephritis Kidney Tissue at Single-Cell Resolution
Nicholas Sugiarto¹, Michelle Curtis², Siddarth Gurajala², Thomas Eisenhaure³, Qian Xiao⁴, Joseph Mears⁵, Arnon Arazi⁶, Paul Hoover⁷, Celine Berthier⁸, Saori Sakaue⁹, Andrea Fava¹⁰, David Hildeman¹¹, E. Steve Woodle¹², Brad Rovin¹³, Jennifer Barnas¹⁴, Maria Dall'Era¹⁵, Chaim Putterman¹⁶, Diane Kamen¹⁷, Maureen McMahon¹⁸, Jennifer Grossman¹⁹, Kenneth Kalunian²⁰, Jeffrey Hodgin²¹, Fernanda Payan Schober²², Mariko Ishimori²³, Michael Weisman²³, William Apruzzese²⁴, Joel Guthridge²⁵, Michael Brenner²⁶, Jennifer Anolik²⁷, David Wofsy²⁸, Judith James²⁵, Deepak Rao⁷, Anne Davidson²⁹, Michelle Petri³⁰, Jill Buyon³¹, Nir Hacohen³², Betty Diamond³³ and Soumya Raychaudhuri⁷, ¹Harvard Medical School, Brookline, MA, ²Harvard Medical School, Boston, ³Broad Institute, Cambridge, MA, ⁴Harvard Medical School, Boston, MA, ⁵Michigan University, Ann Arbor, MI, ⁶Feinstein Institutes for Medical Research, Acton, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸University of Michigan, Ann Arbor, MI, ⁹University of Washington, Yokohama, Japan, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Cincinnati Children's Hospital, Cincinnati, OH, ¹²UC Health, Cincinnati, ¹³The Ohio State University, Columbus, OH, ¹⁴University of Rochester, Rochester, NY, ¹⁵Division of Rheumatology, University of California, San Francisco, CA, ¹⁶Albert Einstein College of Medicine, Safed, Israel, ¹⁷Medical University of South Carolina, Johns Island, SC, ¹⁸UCLA David Geffen School of Medicine, Los Angeles, CA, ¹⁹UCLA, Sherman Oaks, CA, ²⁰UC San Diego, La Jolla, CA, ²¹University of Michigan, Ann Arbor, ²²TTUHSC, El Paso, TX, ²³Cedars-Sinai Medical Center, Los Angeles, CA, ²⁴Pfizer, Boston, ²⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁶Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²⁷University of Rochester Medical Center, Rochester, NY, ²⁸University of California San Francisco, SF, CA, ²⁹Feinstein Institutes for Medical Research, Manhasset, NY, ³⁰Johns Hopkins University School of Medicine, Timonium, MD, ³¹NYU Grossman School of Medicine, New York, NY, ³²Broad Institute of MIT Harvard, Cambridge, MA, ³³The Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Lupus nephritis (LN) is a heterogeneous disease driven by diverse immune and tissue cell types. We defined the cell states in the tissue and…
Abstract Number: 2491 • ACR Convergence 2025
High Prevalence of Autoimmunity and Cancer in Anti-NOR90-positive Patients: A Multicenter Observational Study
Marina Dueñas-Ochoa¹, Cristina Valero², Francisco Morandeira³, Juan Carlos Sáez¹, Maryia Nikitsina⁴, Montserrat Roig Kim⁵, Laia De Daniel Bisbe⁵, Esther Vicente-Rabaneda⁶, Arantza Alfranca¹, Miguel A. González-Gay⁷, Martí Aguilar Coll⁸, Rosario Garcia Vicuña⁶, Javier Narváez⁹ and Santos Castañeda¹⁰, ¹Hospital La Princesa, Madrid, Spain, ²Hospital de la Princesa, Madrid, Spain, ³Department of Immunology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴University Hospital La Princesa, Madrid, Madrid, Madrid, Spain, ⁵Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁶Hospital Universitario de La Princesa, Madrid, Spain, ⁷Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain, ⁸Hospital Bellvitge, Barcelona, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: Anti-Nucleolar Organizer Region 90 (anti-NOR90) antibodies target nucleolar proteins involved in ribosomal RNA transcription and processing, key steps in protein synthesis. These antibodies have…
Abstract Number: 2396 • ACR Convergence 2025
A Machine Learning Algorithm Based on a 15-Autoantibody Profile by a Novel Fully Automated Multiplexed Microarray Immunoassay for the Diagnosis of Autoimmune Connective Tissue Diseases
Gerber Gomez¹, Yipeng Cheng², Kristiana Nita², Michael Hausmann³, Christian Fischer¹ and Yasemin Ataman-Önal³, ¹Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland, ²AliveDx, Edinburgh, United Kingdom, ³AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Detection of relevant autoantibodies is key in the identification of autoimmune connective tissue diseases (CTD). The evaluation of multiple autoantibodies for extended serological profiling…
Abstract Number: 2025 • ACR Convergence 2025
Spectrum of Autoantibodies in CNS Demyelinating Diseases: Clinical, Laboratory and Imaging Associations
Anna Rapti¹, Dimitris Karathanasis², Sylvia Raftopoulou¹, Charalampos Skarlis¹, Clio Mavragani¹ and Maria Eleftheria Evangelopoulos², ¹Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ²First Department of Neurology, School of Medicine, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece
Background/Purpose: Systemic autoimmune diseases (SADs) may present with CNS demyelination, mimicking multiple sclerosis (MS), though driven by distinct immunopathogenic mechanisms. While ANA and aPL are…
Abstract Number: 1850 • ACR Convergence 2025
First American SLE patients demonstrate enhanced lipid metabolism and B cell activation by high-content proteomic analyses
Rufei Lu¹, Tayte Stephens², Carla Guthridge¹, Miles Smith¹, Joseph Kheir¹, Cristina Arriens¹, Joan Merrill³, Marci Beel⁴, Susan Macwana¹, Wade DeJager⁵, Nicholas Domingez¹, Teresa Aberle¹, Joel Guthridge¹ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Science Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴Oklahoma Medical Research Foun, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune diseases with overlapping yet distinct immunopathologies. Proteomic profiling of soluble plasma factors can reveal…
Abstract Number: 1693 • ACR Convergence 2025
Characterizing ANCA-specific B Cells in ANCA-associated Vasculitis
Laura van Dam¹, Mengrui Zhang¹, Shima Parsafar², Audra Horomanski³, Sajede Rasouli², Orr Sharpe², Jolijn van Leeuwen⁴, Tobias Lanz², Cees van Kooten⁴, Onno Teng⁵ and William H. Robinson³, ¹Stanford University, Stanford, CA, ²Stanford University, Stanford, ³Stanford University, Palo Alto, CA, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Leiden University Medical Center, Leiderdorp, Netherlands
Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a severe autoimmune disease, characterized by ANCAs targeting myeloperoxidase (MPO) or proteinase-3 (PR3). ANCA-specific B cells have…
Abstract Number: 1537 • ACR Convergence 2025
Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease
Melanie Hagen¹, Fabian Müller², Andreas Wirsching¹, Soraya Kharboutli³, Silvia Spoerl³, Christina Duesing⁴, Tobias Krickau⁵, Markus Metzler⁵, Simon Völkl³, Michael Aigner³, Sascha Kretschmann³, Ingrid Vasova³, Marc Saake⁵, Stefan Schliep⁵, Torsten Kubacki⁶, Nicolas Hunzelmann⁶, Laura Bucci¹, Jule Taubmann⁷, Christina Bergmann¹, Andrea-Hermina Györfi⁸, Sascha Dietrich⁹, Jörg Distler¹⁰, Ricardo Grieshaber-Bouyer¹¹, Andreas Mackensen¹² and Georg Schett¹³, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²University Hospital of Erlangen, Erlangen, Germany, ³Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Klinik für Rheumatologie, Düsseldorf, Germany, ⁵Friedrich-Alexander-Universität Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁶University and University Hospital Cologne, Cologne, Germany, Cologne, Germany, ⁷Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁸Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁹Heinrich Heine University Duesseldorf, University Hospital Duesseldorf, Duesseldorf, Germany, ¹⁰University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment strategies for severe B-cell driven autoimmune diseases (AID) like Systemic Lupus erythematosus (SLE), Systemic…
Abstract Number: 1387 • ACR Convergence 2025
Demographic and Clinical Characteristics of Patients Diagnosed With Sjögren’s Disease Using Electronic Health Records and Linked Claims Data From the US Excellence Network in RheumatoloGY (ENRGY) Practice-Based Research Network
Jeffrey Curtis¹, Emily Holladay², Antton Egana³, Anjana Lalla³, Yujie Su⁴, Fenglong Xie⁵, Amy Mudano⁴, Shanette Daigle⁴ and Sara McCoy⁶, ¹Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ²University of Alabama at Birmingham, Edmond, OK, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, ⁵The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Wisconsin–Madison, Madison, WI
Background/Purpose: Sjögren’s disease (SjD) is a chronic autoimmune disease characterized by systemic symptoms such as dryness, fatigue, musculoskeletal pain, and extraglandular manifestations. SjD may overlap…
Abstract Number: 1190 • ACR Convergence 2025
IgG4-related disease with comorbid autoimmune diseases: a retrospective study from a large cohort
Xinli Yang¹, Wen Zhang², Jiaxin zhou³ and Yuxue Nie⁴, ¹Peking Union Medical College, Dong Cheng Qu, China (People's Republic), ²Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ³Peking Union Medical College Hospital, Beijing, China (People's Republic), ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, Dong Cheng Qu, China (People's Republic)
Background/Purpose: This study aimed to explore the clinical characteristics, treatment, and prognosis of IgG4-related disease (IgG4-RD) patients with comorbid autoimmune diseases (AIDs).Methods: A total of…
Abstract Number: 1092 • ACR Convergence 2025
Prior history of arthritis and PD-1 over PD-L1 blockade predispose to immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
Binod Kc¹, Aakritee Sharma Subedi¹, Salome Walsh¹, Areeba Memon¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by enhancing the immune system's ability to fight cancer. However, their use is associated with immune-related…
Abstract Number: 0976 • ACR Convergence 2025
LMPTP Drives Fibrosis in Systemic Sclerosis via TGF-beta Signaling Activation
Yuan Zhan¹, Colton Sanders², Michael Diaz², Jinmin Miao³, Arminja Kettenbach⁴, Zhong-Yin Zhang⁵, Paul Wolters⁶, Francesco Boin⁷, Stephanie Stanford² and Nunzio Bottini⁸, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of California San Diego, San Diego, CA, ³Purdue University, West Lafayette, IN, ⁴Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁵Purdue University, Department of Medicinal Chemistry and Molecular Pharmacology, West Lafayette, IN, ⁶University of California San Francisco, San Francisco, CA, ⁷Cedars-Sinai Medical Center, Beverly Hills, CA, ⁸Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: The identification of effective and safe anti-fibrotic agents is a critical unmet need in systemic sclerosis (SSc). Although fibrosis in SSc is driven by…
Abstract Number: 0915 • ACR Convergence 2025
A fusion of TACI variant and anti-IFNAR antibody with greater therapeutic effect on related autoimmune disease models
Yuhao Qin¹, Huan Wang¹, Han Gao¹, Chongqi Zhang¹, Chengpan Wang¹, yanru fan¹, wei ye¹, yuan lin¹, Lu Su², Wenming Ren¹ and cheng liao¹, ¹Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China (People's Republic), ²Jiangsu Hengrui Pharmaceuticals, Shanghai, Shanghai, China
Background/Purpose: Pathological elevation of type I interferon (IFN-I) , B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) has been robustly documented across multiple autoimmune…
Abstract Number: 0678 • ACR Convergence 2025
Targeting the plasma cell niche in systemic sclerosis: A case series about the bispecific anti-BCMAxCD3 antibody teclistamab in severe, treatment-refractory patients
Andrea-Hermina Györfi¹, Ayla Nadja Stuetz², Christina Duesing³, Laura-Marie Lahu⁴, Franca Sophie Deicher⁵, Yi-Nan Li⁶, Celine van Saan⁵, Alexandru-Emil Matei⁷, Alexander Hoelscher⁵, Peter-Martin Bruch⁸, Sarah Koziel⁸, Manuel Roehrich⁹, Mareike Cramer¹⁰, Bernhard Homey⁵, Bjoern Buehring¹¹, Alexander Kreuter¹², Aleksandar Radujkovic⁵, Claus Peter Heußel¹³, Hanns-Martin Lorenz¹⁴, Ricardo Grieshaber-Bouyer¹⁵, Georg Schett¹⁶, Jörg Distler¹⁷ and Wolfgang Merkt¹⁸, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ³Klinik für Rheumatologie, Düsseldorf, Germany, ⁴Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, ⁵Uniklinik Düsseldorf, Düsseldorf, Germany, ⁶University Hospital of Düsseldorf, Düsseldorf, Germany, ⁷Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ⁸University Hospital Düsseldorf, Dusseldorf, Germany, ⁹Universitätsmedizin Mainz, Mainz, ¹⁰University Hospital Düsseldorf, Düsseldorf, Germany, ¹¹Bergisches Rheuma-Zentrum, Krankenhaus St Josef, Wuppertal, Germany, ¹²HELIOS St. Elisabeth Clinic Oberhausen, University Witten-Herdecke, Oberhausen, Germany, ¹³Thoraxklinik, University of Heidelberg, Heidelberg, ¹⁴Universitétsklinikum Heidelberg, Heidelberg, Germany, ¹⁵University Hospital Erlangen, Erlangen, Germany, ¹⁶Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹⁷University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹⁸University Hospital Düsseldorf, Düsseldorf, Germany
Background/Purpose: Systemic sclerosis (SSc) possesses the highest case-related mortality of all rheumatic diseases. B cell-targeting, including CD19-targeting CAR-T cells, has shown efficacy but failed to…
Abstract Number: 0858 • ACR Convergence 2025
IgA Anti-β2GPI Antibodies Drive Proatherogenic Myeloid Activation and Vascular Dysfunction in APS
Kavya Sugur¹, Chao Liu², Emily Chong³, Srilakshmi Yalavarthi⁴, Katarina Kmetova⁵, Wenying Liang⁶, Emily Becker⁶, Gavin Poppei⁶, Cyrus Sarosh⁷, NaveenKumar Somanathapura³, Ajay Tambralli³, Jason S. Knight³ and Yu (Ray) Zuo³, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ²University of Michigan, Superior Charter Twp, MI, ³University of Michigan, Ann arbor, MI, ⁴Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, ⁵Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁶University of Michigan, Ann arbor, ⁷University of Michigan, Temperance, MI
Background/Purpose: Cardiovascular disease is a major cause of morbidity and mortality in antiphospholipid syndrome (APS), with rates of accelerated atherosclerosis comparable to those seen in…

« Previous Page
1
…
7
8
9
10
11
…
101
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].